Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% Higher

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 0.4% during trading on Friday . The company traded as high as $7.60 and last traded at $7.44. 565,754 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 5,927,254 shares. The stock had previously closed at $7.41.

Analyst Ratings Changes

A number of research analysts have commented on the stock. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The company has a market capitalization of $1.73 billion, a PE ratio of -4.55 and a beta of 0.83. The stock’s 50 day simple moving average is $7.55 and its 200-day simple moving average is $9.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) earnings per share. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $7.12, for a total transaction of $81,502.64. Following the sale, the director now directly owns 7,132,769 shares in the company, valued at $50,785,315.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at $6,388,573.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64. Following the sale, the director now owns 7,132,769 shares in the company, valued at $50,785,315.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 255,682 shares of company stock worth $1,990,912. Company insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. National Bank of Canada FI boosted its holdings in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $47,000. GAMMA Investing LLC boosted its holdings in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.